Analyst Price Target is $25.00
▲ +235.12% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ProPhase Labs in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 235.12% upside from the last price of $7.46.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in ProPhase Labs.
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through saliva and nasal swab methods, as well as other respiratory pathogen panel testing services, including Influenza A and B, and others. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was incorporated in 1989 and is headquartered in Garden City, New York.